Arcus Provides Update on Phase 3 STAR-221 Study and Concentrates Its R&D Investment on Casdatifan and Emerging Inflammation and Immunology Portfolio

Core Viewpoint - Arcus Biosciences, Inc. has announced the discontinuation of the Phase 3 STAR-221 study due to futility, based on the recommendation from the Independent Data Monitoring Committee [1] Company Summary - Arcus Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing differentiated molecules and combination therapies for cancer, inflammatory, and autoimmune diseases [1] - The study was being conducted in partnership with Gilead Sciences, Inc. [1]